Magnus Financial Group LLC Sells 15,138 Shares of Johnson & Johnson $JNJ

Magnus Financial Group LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 41.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,402 shares of the company’s stock after selling 15,138 shares during the quarter. Magnus Financial Group LLC’s holdings in Johnson & Johnson were worth $3,968,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Clark Asset Management LLC boosted its stake in shares of Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after purchasing an additional 3,025 shares in the last quarter. Treasurer of the State of North Carolina boosted its position in Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after buying an additional 94,957 shares during the period. Avanza Fonder AB grew its stake in shares of Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after buying an additional 6,566 shares during the last quarter. Talbot Financial LLC increased its holdings in shares of Johnson & Johnson by 4.6% in the third quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after buying an additional 6,143 shares during the period. Finally, Liberty One Investment Management LLC lifted its stake in shares of Johnson & Johnson by 83.9% in the 3rd quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock valued at $68,040,000 after acquiring an additional 167,353 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Raymond James Financial lifted their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Citigroup raised their price target on shares of Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Trading Down 0.3%

NYSE JNJ opened at $218.81 on Friday. The stock’s 50 day moving average is $205.82 and its 200 day moving average is $186.95. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $527.18 billion, a PE ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $220.11.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.